Shinpoong Pharmaceutical Co.,Ltd (KRX:019170)
South Korea · Delayed Price · Currency is KRW 10,470
+220 (2.15%)
At close: Apr 8, 2026
KRX:019170 Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 8,825 | -15,387 | -57,325 | -35,377 | -11,584 |
Depreciation & Amortization | 11,393 | 11,963 | 11,908 | 12,803 | 12,675 |
Loss (Gain) From Sale of Assets | -2.54 | -6.89 | -39.65 | -18.31 | -49.02 |
Asset Writedown & Restructuring Costs | - | - | - | 703.23 | - |
Loss (Gain) From Sale of Investments | 2,820 | -1,216 | 1,011 | -845.62 | -253.64 |
Loss (Gain) on Equity Investments | - | - | 6,514 | 697.09 | -2,620 |
Provision & Write-off of Bad Debts | -982.49 | -86.42 | 2,939 | 1,395 | -937.06 |
Other Operating Activities | 5,290 | -588.5 | 9,834 | 6,692 | -58,525 |
Change in Accounts Receivable | -1,121 | 3,090 | 5,805 | -1,225 | 8,199 |
Change in Inventory | -3,628 | -942.29 | -7,049 | 972.41 | 1,774 |
Change in Accounts Payable | -2,720 | 209.57 | -2,295 | -435.91 | 3,385 |
Change in Other Net Operating Assets | -2,620 | -12,190 | 3,890 | -11,806 | -23,093 |
Operating Cash Flow | 17,254 | -15,155 | -24,808 | -26,444 | -71,028 |
Capital Expenditures | -3,477 | -5,569 | -14,888 | -5,323 | -4,425 |
Sale of Property, Plant & Equipment | 0.37 | 6.9 | 53.26 | 1.01 | 16.63 |
Sale (Purchase) of Intangibles | -513.09 | -519.7 | -142.52 | -334.9 | -953.63 |
Investment in Securities | -10,716 | 2,473 | -1,182 | 48,846 | 54,379 |
Other Investing Activities | 0 | 9,192 | -150 | 8.01 | 11.16 |
Investing Cash Flow | -14,706 | 5,583 | -16,309 | 43,197 | 49,028 |
Long-Term Debt Issued | 11,885 | 12,000 | 45,000 | - | 10,000 |
Long-Term Debt Repaid | -8,180 | -5,843 | -1,761 | -1,869 | -11,262 |
Net Debt Issued (Repaid) | 3,705 | 6,157 | 43,239 | -1,869 | -1,262 |
Common Dividends Paid | - | - | - | - | -5,156 |
Other Financing Activities | -0 | 40 | -40 | - | - |
Financing Cash Flow | 3,705 | 6,197 | 43,199 | -1,869 | -6,418 |
Foreign Exchange Rate Adjustments | -806.21 | 1,561 | 27.29 | -830.79 | 252.16 |
Miscellaneous Cash Flow Adjustments | -0 | 0 | -0 | -0 | 0 |
Net Cash Flow | 5,447 | -1,814 | 2,109 | 14,054 | -28,166 |
Free Cash Flow | 13,776 | -20,724 | -39,696 | -31,767 | -75,453 |
Free Cash Flow Margin | 5.87% | -9.37% | -19.82% | -15.18% | -39.87% |
Free Cash Flow Per Share | 268.50 | -405.39 | -774.37 | -619.69 | -1471.90 |
Cash Interest Paid | 2,607 | 2,566 | 1,647 | 2.06 | 158.16 |
Cash Income Tax Paid | -317.29 | 3,312 | -2,962 | -554.25 | 65,648 |
Levered Free Cash Flow | 8,628 | -5,184 | -26,774 | -16,386 | -48,674 |
Unlevered Free Cash Flow | 10,308 | -3,539 | -25,700 | -16,348 | -48,548 |
Change in Working Capital | -10,089 | -9,832 | 350.99 | -12,494 | -9,735 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.